JP6616284B2 - 特異的結合分子の人工ライブラリー - Google Patents

特異的結合分子の人工ライブラリー Download PDF

Info

Publication number
JP6616284B2
JP6616284B2 JP2016509450A JP2016509450A JP6616284B2 JP 6616284 B2 JP6616284 B2 JP 6616284B2 JP 2016509450 A JP2016509450 A JP 2016509450A JP 2016509450 A JP2016509450 A JP 2016509450A JP 6616284 B2 JP6616284 B2 JP 6616284B2
Authority
JP
Japan
Prior art keywords
antigen
sequence
vnar
library
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016509450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524463A (ja
JP2016524463A5 (enExample
Inventor
ジェーン バレル，キャロライン
ジェームス ジョナサン フィンレイ，ウィリアム
ダーマンイン−シーハン，アルフレッド
ジャスティン ラドクリフ ポーター，アンドリュー
Original Assignee
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン filed Critical ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン
Publication of JP2016524463A publication Critical patent/JP2016524463A/ja
Publication of JP2016524463A5 publication Critical patent/JP2016524463A5/ja
Application granted granted Critical
Publication of JP6616284B2 publication Critical patent/JP6616284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
JP2016509450A 2013-04-23 2014-04-23 特異的結合分子の人工ライブラリー Active JP6616284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058251 WO2014173959A2 (en) 2013-04-23 2014-04-23 Synthetic library of specific binding molecules

Publications (3)

Publication Number Publication Date
JP2016524463A JP2016524463A (ja) 2016-08-18
JP2016524463A5 JP2016524463A5 (enExample) 2017-06-08
JP6616284B2 true JP6616284B2 (ja) 2019-12-04

Family

ID=50543598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016509450A Active JP6616284B2 (ja) 2013-04-23 2014-04-23 特異的結合分子の人工ライブラリー
JP2016509455A Active JP6591964B2 (ja) 2013-04-23 2014-04-23 Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016509455A Active JP6591964B2 (ja) 2013-04-23 2014-04-23 Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離

Country Status (11)

Country Link
US (3) US10472410B2 (enExample)
EP (3) EP2989203B1 (enExample)
JP (2) JP6616284B2 (enExample)
KR (2) KR102320189B1 (enExample)
CN (2) CN105492610B (enExample)
AU (3) AU2014257549B2 (enExample)
BR (2) BR112015026729A2 (enExample)
CA (2) CA2909923A1 (enExample)
DK (1) DK2989203T3 (enExample)
RU (2) RU2015146419A (enExample)
WO (2) WO2014173975A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー
EP3160995A2 (en) * 2014-06-26 2017-05-03 Ossianix Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
CN107074961A (zh) * 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11919949B2 (en) 2017-09-27 2024-03-05 Elasmogen Ltd Specific binding molecules
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
US12351642B2 (en) 2018-09-14 2025-07-08 Ossianix, Inc. TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
US12694953B2 (en) 2019-02-11 2026-07-28 Arizona Board Of Regents On Behalf Of Arizona State University Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
CA3177089A1 (en) * 2020-05-01 2021-11-04 Yi Shi Compositions and methods for identifying nanobodies and nanobody affinities
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1660186B1 (en) * 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
DE602004032042D1 (de) * 2003-08-27 2011-05-12 Proterec Ltd Bibliotheken rekombinanter chimärischer proteine
DK1751181T3 (da) 2004-06-02 2012-11-26 Adalta Pty Ltd BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006003999A1 (ja) * 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
US20100129368A9 (en) 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
WO2010040175A1 (en) * 2008-10-06 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
CA2738801A1 (en) * 2008-10-07 2010-04-15 Zap Holdings Limited Synchronization of relational databases with olap cubes
US8496933B2 (en) * 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains
WO2012073048A2 (en) * 2010-12-03 2012-06-07 Cyclogenix Ltd Binding peptides i
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー

Also Published As

Publication number Publication date
JP2016524463A (ja) 2016-08-18
US11459377B2 (en) 2022-10-04
CN105492610A (zh) 2016-04-13
DK2989203T3 (da) 2020-02-17
US10202438B2 (en) 2019-02-12
US20160176951A1 (en) 2016-06-23
CA2909921C (en) 2022-12-06
BR112015026716A2 (pt) 2017-09-05
KR20160015220A (ko) 2016-02-12
WO2014173959A2 (en) 2014-10-30
AU2014257549B2 (en) 2019-04-18
EP3683312A3 (en) 2020-09-16
RU2015146419A (ru) 2017-05-26
EP2989203A2 (en) 2016-03-02
JP6591964B2 (ja) 2019-10-16
EP2989204B1 (en) 2019-03-20
CN105531370A (zh) 2016-04-27
US20200002403A1 (en) 2020-01-02
RU2015146418A3 (enExample) 2018-05-07
WO2014173959A3 (en) 2015-01-29
CA2909923A1 (en) 2014-10-30
AU2014257549A1 (en) 2015-11-26
RU2015146418A (ru) 2017-05-26
BR112015026729A2 (pt) 2017-09-05
US20160068600A1 (en) 2016-03-10
EP3683312B1 (en) 2022-09-07
CA2909921A1 (en) 2014-10-30
CN105492610B (zh) 2020-08-25
US10472410B2 (en) 2019-11-12
AU2019206064A1 (en) 2019-08-08
EP3683312A2 (en) 2020-07-22
KR102320189B1 (ko) 2021-11-03
WO2014173975A1 (en) 2014-10-30
EP2989203B1 (en) 2019-11-13
KR20160010466A (ko) 2016-01-27
AU2014257565A1 (en) 2015-11-26
EP2989204A1 (en) 2016-03-02
JP2016524592A (ja) 2016-08-18

Similar Documents

Publication Publication Date Title
US11459377B2 (en) Synthetic library of specific binding molecules
JP6639464B2 (ja) Ｉｇ様分子を生産する方法、Ｉｇ様分子の混合物、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法および培養物
US20200115702A1 (en) Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
JP2020528736A (ja) イヌ抗体ライブラリ
JP2021521781A (ja) 三価三重特異性抗体構築物
US20240376639A1 (en) Fast-track humanisation of specific binding molecules
JP2018507254A (ja) 抗代替軽鎖抗体
JP2021518168A (ja) 拮抗的抗原結合タンパク質
JP2023179537A (ja) 改変されたヒト可変ドメイン
KR20230128290A (ko) 가변 중쇄 전용 라이브러리, 이의 제조 방법, 및 이의용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191107

R150 Certificate of patent or registration of utility model

Ref document number: 6616284

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250